M2 Pharma - Therapy Areas

FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients with a Severe form of Scleroderma

8 July 2020 - - The US Food and Drug Administration has approved US-based biotechnology company Talaris Therapeutics, Inc's Investigational New Drug application for the evaluation of Talaris'...

Cyxone (publ) names new senior scientific Aadvisor

7 July 2020 - Cyxone (publ), a Sweden-based biotech company, has named Dr Maarten Kraan as its new senior scientific advisor for the company's project for Rabeximod in rheumatoid arthritis, it wa...

HSS expects anakinra to help select COVID-19 patients avoid mechanical ventilation

1 July 2020 - Academic medical centre Hospital for Special Surgery (HSS) stated on Tuesday that the approved immunosuppressive drug anakinra used to treat rheumatoid arthritis and neonatal-onset multi...

Cytocom Completes Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients

29 June 2020 - - US-based biopharmaceutical company Cytocom, Inc has completed a Type B pre-IND meeting with the US Food and Drug Administration in relation to the company's planned Phase 2 clini...

Celltex Therapeutics Receives FDA Approval for Phase II Clinical Trial Using Mesenchymal Stem Cells as a Prophylactic Against COVID-19

26 June 2020 - - Houston, Texas-based biotechnology company Celltex has received approval from the US Food and Drug Administration to proceed with the company's Investigational New Drug applicati...

Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate

25 June 2020 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) and US-based delivery technologies, development, and manufacturing solutions provider Catalent, Inc. (NYSE: CTLT) have forg...